Is BioAtla Inc. (NASDAQ:BCAB) an excellent stock to buy at the moment?

The price of BioAtla Inc. (NASDAQ: BCAB) closed at $3.48 in the last session, up 8.07% from day before closing price of $3.22. In other words, the price has increased by $+0.2600 from its previous closing price. On the day, 1383050 shares were traded. BCAB stock price reached its highest trading level at $3.5200 during the session, while it also had its lowest trading level at $3.2200.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



We take a closer look at BCAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.70 and its Current Ratio is at 7.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on September 15, 2022, initiated with a Mkt Outperform rating and assigned the stock a target price of $17.

On May 05, 2022, Credit Suisse Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $35 to $5.

On March 21, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on March 21, 2022, with a $25 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 19 when MCBRINN SYLVIA bought 3,700 shares for $8.33 per share. The transaction valued at 30,813 led to the insider holds 9,125 shares of the business.

MCBRINN SYLVIA bought 2,000 shares of BCAB for $16,540 on Nov 22. The Director now owns 5,425 shares after completing the transaction at $8.27 per share. On Sep 13, another insider, MCBRINN SYLVIA, who serves as the Director of the company, bought 1,000 shares for $8.20 each. As a result, the insider paid 8,200 and bolstered with 3,000 shares of the company.

Stock Price History:

Over the past 52 weeks, BCAB has reached a high of $12.15, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is 8.0654, while the 200-Day Moving Average is calculated to be 5.9848.

Shares Statistics:

According to the various share statistics, BCAB traded on average about 863.43K shares per day over the past 3-months and 2.21M shares per day over the past 10 days. A total of 47.32M shares are outstanding, with a floating share count of 40.18M. Insiders hold about 4.40% of the company’s shares, while institutions hold 58.40% stake in the company. Shares short for BCAB as of Oct 13, 2022 were 5.09M with a Short Ratio of 4.16M, compared to 4.03M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 13.56% and a Short% of Float of 18.91%.

Earnings Estimates

The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.8 for the current quarter, with a high estimate of -$0.73 and a low estimate of -$0.9, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.75, with high estimates of -$0.45 and low estimates of -$0.92.

Analysts are recommending an EPS of between -$2.6 and -$3.24 for the fiscal current year, implying an average EPS of -$2.99. EPS for the following year is -$2.98, with 7 analysts recommending between -$1.32 and -$4.32.